Objective: Mutations in the type IV collagen alpha 1 gene (COL4A1) cause dominantly inherited cerebrovascular disease. We seek to determine the extent to which COL4A1 mutations contribute to sporadic, nonfamilial, intracerebral hemorrhages (ICHs). Methods: We sequenced COL4A1 in 96 patients with sporadic ICH. The presence of putative mutations was tested in 145 ICH-free controls. The effects of rare coding variants on COL4A1 biosynthesis were compared to previously validated mutations that cause porencephaly, small vessel disease, and hereditary angiopathy, nephropathy, aneurysms, and cramps (HANAC) syndrome. Results: We identified 2 rare nonsynonymous variants in ICH patients that were not detected in controls, 2 rare nonsynonymous variants in controls that were not detected in patients, and 2 common nonsynonymous variants that were detected in patients and controls. No variant found in controls affected COL4A1 biosynthesis. Both variants (COL4A1 P352L and COL4A1 R538G ) found only in patients changed conserved amino acids and impaired COL4A1 secretion much like mutations that cause familial cerebrovascular disease. Interpretation: This is the first assessment of the broader role for COL4A1 mutations in the etiology of ICH beyond a contribution to rare and severe familial cases and the first functional evaluation of the biosynthetic consequences of an allelic series of COL4A1 mutations that cause cerebrovascular disease. We identified 2 putative mutations in 96 patients with sporadic ICH and showed that these and other previously validated mutations inhibit secretion of COL4A1. Our data support the hypothesis that increased intracellular accumulation of COL4A1, decreased extracellular COL4A1, or both, contribute to sporadic cerebrovascular disease and ICH. ANN NEUROL 2012;71:470-477 S trokes are common and devastating neurological events with poor clinical outcomes for which there are few effective treatments. Intracerebral hemorrhages (ICHs) are the most fatal and least treatable form of stroke. Although only accounting for 10% to 15% of all strokes, ICH is associated with the highest rate of mortality.
S
trokes are common and devastating neurological events with poor clinical outcomes for which there are few effective treatments. Intracerebral hemorrhages (ICHs) are the most fatal and least treatable form of stroke. Although only accounting for 10% to 15% of all strokes, ICH is associated with the highest rate of mortality. 1 Up to 50% of individuals die within the first year following ICH and the majority of survivors suffer lifelong disability. 2 Approximately 90,000 people suffer from ICH each year in the United States, and this number is expected to double in the next 50 years as life expectancies increase. 1 Current therapies offer little hope for substantially improving the outcome. Prevention is therefore of paramount importance for reducing the personal and societal burden of ICH. Identifying the genetic factors that predispose to ICH allows identification of individuals who are at greater risk and facilitates understanding of the biological mechanisms underlying disease and the promise of novel drug targets. Sporadic ICH generally occurs in the elderly and most commonly occurs in the setting of cerebral amyloid angiopathy (CAA) or hypertensive vasculopathy.
Epidemiological studies have identified modifiable risk factors that contribute to ICH, notably alcohol consumption, hypertension, and cigarette smoking, but suggest that they account for only small proportions of the overall attributable risk. 3 Mutations in several genes are well established to contribute to familial syndromic ICH in the young; unfortunately, to date, these have not proven to contribute broadly to sporadic cases. Dominant mutations in the gene coding for type IV collagen alpha 1 (COL4A1) cause highly penetrant cerebrovascular diseases, including ICH, and are being identified in an increasing number of patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and its binding partner, COL4A2, are the most abundant and ubiquitous basement membrane proteins and are present in cerebral vascular basement membranes. One COL4A2 and 2 COL4A1 peptides assemble into heterotrimers within the endoplasmic reticulum (ER) before being transported to the Golgi and secreted into the extracellular space. 15, 16 Heterotrimers associate into a meshwork and form flexible sheets that provide structure and strength to basement membranes in the extracellular space. At the carboxy termini of COL4A1 and COL4A2 are globular domains responsible for conferring binding partner specificity and initiating heterotrimer formation within the ER. 17 The amino terminal domains are responsible for higher-order intertrimer associations in the extracellular matrix. The vast majority (>90%) of the COL4A1 protein consists of a long, triple helix-forming domain composed of repeating Gly-Xaa-Yaa amino acid residues that are characteristic of collagens. Extensive data from many types of collagens in several species demonstrate that missense and splice-site mutations that disrupt triple helix assembly cause protein misfolding and are highly pathogenic. 18 This is also true for COL4A1. To date, 11 of 13 mutations identified in mice 4, 19, 20 and 21 of 24 mutations identified in human patients occur within the triple helix-forming domain. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [21] [22] [23] The phenotypes resulting from COL4A1 mutations are genetically complex and pleiotropic; often involving other organ systems. Mutations in COL4A1 have already been reported to underlie a spectrum of cerebrovascular diseases. We demonstrated that mice with a mutation in Col4a1 had prenatal and perinatal ICH, porencephalic cavities, progressive, multifocal and recurrent ICH, and, occasionally, subarachnoid hemorrhages, 4, 5 in addition to other ocular, renal, and muscular phenotypes. 21 To date, we, and others, have discovered independent COL4A1 mutations in multiple patients with porencephaly. 4, 6, [22] [23] [24] or with other forms of cerebrovascular diseases. 5, [7] [8] [9] [10] [11] [12] [13] [14] 22, 23 We identified a COL4A1 mutation in a French family diagnosed with a multisystem small-vessel disease that not only affected the cerebrovascular system but also the renal and retinal vasculature, demonstrating that COL4A1 mutations affect multiple organ systems in human patients. 5 More recently, mutations were identified in 6 families presenting with a multisystem disorder referred to as hereditary angiopathy, nephropathy, aneurysms, and cramps (HANAC) syndrome; which is reported to be associated with milder cerebrovascular diseases than that observed in other patients with COL4A1 mutations. 9, 13, 25, 26 The mutations in these patients cluster within a 31-amino acid region of the COL4A1 protein that encompasses putative integrin binding domains, leading to the suggestion that allelic heterogeneity might contribute to the variable expressivity of COL4A1-related phenotypes. In addition to a potential role for allelic heterogeneity, we have shown that genetic context can modify the penetrance and severity of phenotypes caused by a Col4a1 mutation in mice 27 and that environmental factors (including birth trauma, anticoagulant use, and head trauma) also likely influence the clinical manifestation of disease in individuals with a COL4A1 mutation. 5 Together, these data show that COL4A1 mutations can cause diverse forms of cerebrovascular disease and identify COL4A1 as a strong candidate for involvement in sporadic ICH. Here, we investigated the potential role of COL4A1 mutations in sporadic (nonfamilial) ICH not caused by arteriovenous malformations, tumors, or impaired coagulation. We identified 2 novel putative COL4A1 mutations in patients diagnosed with sporadic CAA or presumed hypertension-related ICH. To test the biosynthetic consequences of these putative mutations, we developed and validated a cell culture-based functional assay using nonpathogenic polymorphisms and previously confirmed disease-causing mutations. We demonstrated that COL4A1 proteins containing a known mutation or 1 of the putative mutations identified in this study impair secretion of COL4A1 and lead to protein accumulation within cells. The findings presented herein raise the possibility that COL4A1 mutations may underlie a significant proportion of new cases of ICH every year in the United States and that therapies aimed at promoting protein folding might be effective in preventing hemorrhagic strokes in some patients.
Patients and Methods

Patient Selection
Cases were selected from among 800 consecutive patients with ICH presenting to Massachusetts General Hospital. All individuals were prospectively characterized by neurologists without knowledge of this study, as well as by neuroimaging, and were categorized according to diagnostic criteria (the Boston Criteria) that have been developed and validated. 28 For the present study, 48 individuals with probable CAA-related ICH and 48 individuals with presumed hypertension-related deep ICH were selected according to the inclusion and exclusion criteria published previously 26 (summarized in Supporting Table S1 ).
Patients were chosen who had adequate DNA for sequencing and appropriate consent to share samples between institutions.
The details for the patients included in this study are listed in Table 1 . During the collection of patient samples we obtained DNA from ethnically and age-matched individuals who were free of a history of hemorrhagic stroke and who were drawn from the primary care practices at Massachusetts General Hospital. All participants provided informed consent for participation and the Massachusetts General Hospital Institutional Review Board approved all study procedures.
Genomic Sequence Analysis
Genomic DNA (10ng/ll) was amplified using 44 sets of primers 21 that cover the entire coding sequence for each exon in addition to the flanking intronic regions (50 nucleotides for most introns but never less than 20 nucleotides) of COL4A1. Direct sequencing was performed using ABI BigDye v3.1 and analyzed using Sequencher software (Gene Codes Corporation, Ann Arbor MI).
Functional Analysis of COL4A1 Variants
HT1080 human fibrosarcoma cells were transfected using Superfect reagent (Qiagen, Valencia CA) with the expression vector pReceiver-M02 vector (GeneCopoeia, Rockville MD) containing a cytomegalovirus (CMV) promoter upstream of a control (NM_001845.2) or variant COL4A1 cDNA clone. Variants were introduced by site-directed mutagenesis performed at GeneCopoeia or using a QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA). After 12 days of G418 selection (600lg/ml), individual surviving clones were isolated and expanded in presence of 600lg/ml of G148.
Stably transfected HT1080 cells were cultured in Dulbecco's modified Eagle's medium, supplemented with penicillin, streptomycin, nonessential amino acids, glutamine, sodium pyruvate, G418 (250lg/ml for maintenance), 10% fetal bovine serum (FBS) at 37 C in 5% CO 2 in a humid atmosphere until they reach 80% to 90% confluence. Ascorbic acid (50lg/ml) was added overnight, and the following day cells were serumdeprived for 24 hours in the presence of ascorbic acid. Cells were then harvested and lysed in Laemmli buffer for subsequent Western blot analysis. The conditioned medium was collected at the same time and supplemented with protease inhibitors (Pierce, Rockford IL).
Proteins present in the whole-cell lysate and conditioned medium were separated on 4% to 15% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and transferred to polyvinylidene fluoride membranes (BioRad, Hercules CA). Membranes were blocked for 2 hours at room temperature in 5% nonfat milk in Tris-buffered saline (TBS) containing 0.1% Tween-20, and overnight at 4 C in 3% bovine serum albumin (BSA) in TBS.
Membranes were then incubated with a rat anti-COL4A1 (H11) monoclonal antibody (1:150; Shigei Medical Research Institute, Japan) in 1% BSA in TBS for 3 hours at room temperature and were washed in TBS containing 0.1% Tween-20, incubated 2 hours at room temperature with horseradish peroxidase-conjugated secondary antibody raised in donkey (anti-rat immunoglobulin G [IgG] 1:10 000; Jackson Immunoresearch, West Grove PA) diluted in 5% nonfat milk in TBS containing 0.1% Tween-20. Immunoreactivity was visualized using chemiluminescence (Amersham ECL, Ge Healthcare Piscataway NJ). Densitometric analysis was performed on low exposure images using the NIH Image J software (National Institutes of Health). For quantitative analysis of the ratio of secreted to intracellular COL4A1 protein, the amount of COL4A1 detected in the conditioned medium was divided by the amount of intracellular COL4A1. 
Results
We resequenced all 52 exons of COL4A1, including flanking intronic sequences, for the selected patient cohort (see Table 1 ) and we identified 65 sequence variants-19 coding and 46 noncoding (Supporting Table  S2 ). Of the 19 coding single nucleotide polymorphisms (SNPs), 4 were nonsynonymous and 15 were synonymous variants (Table 2) . We resequenced 290 control chromosomes for each exon in which a coding variant was found. We identified an additional 7 SNPs in control samples; 3 were noncoding, 2 were coding and synonymous and 2 were coding and nonsynonymous. Two sporadic (nonfamilial) ICH patients had nonsynonymous SNPs that were not found in ethnicallymatched control chromosomes. Patient 1 was a 73-yearold Hispanic woman who presented with a generalized tonic-clonic seizure followed by left-sided weakness in the setting of oral warfarin anticoagulation therapy for aortic valve replacement (admission international normalized ratio [INR] 2.8). Computer tomography (CT) imaging identified a small right temporal ICH (8cc) and magnetic resonance imaging (MRI) identified lobar microbleeds, thus qualifying the patient for a diagnosis of probable CAA according to the Boston Criteria. 28 This patient had a cytidine to thymidine transition at nucleotide c.C1055T in exon 19 that resulted in a proline to leucine substitution at position 352 of the peptide sequence (COL4A1 P352L ), which corresponds to the Y position of a Gly-Xaa-Yaa repeat within the triple helixforming domain of the protein (Fig 1) . This variant was not identified in 290 control chromosomes. As shown in an alignment of COL4A1 orthologs from 11 species, a proline residue at this position is highly conserved across all species (see Fig 1) . Patient 2 was a 55-year-old man of EuropeanAmerican ancestry presenting with a large right putaminal ICH (bleeding volume at presentation was 65cc) causing acute-onset left arm, face, and leg weakness and depressed consciousness (Glasgow Coma Scale: 8). Medical history was significant for hypertension, type 2 diabetes and aspirin use (81mg/day). The ICH location and history of hypertension are consistent with a diagnosis of probable hypertensive hemorrhage. The variant found in Patient 2 is a cytidine to guanosine transversion at nucleotide c.C1612G in exon 25, leading to an arginine to glycine substitution at position 538 (COL4A1 R538G ) of the COL4A1 peptide sequence (see Fig 1) . This putative mutation was not identified in 282 control chromosomes. As illustrated in an alignment of COL4A1 orthologs from 11 species, the arginine residue is conserved in all mammals (see Fig 1) .
Missense mutations within the triple helix-forming domain of many different types of collagens from many different species disrupt heterotrimer formation, leading to decreased heterotrimer secretion and subsequent intracellular accumulation of misfolded proteins. To test the hypothesis that COL4A1 P352L and COL4A1 R538G might lead to impaired secretion of the COL4A1/A2 heterotrimers, we measured the relative ratio of extracellular to intracellular COL4A1 using a cell culture-based secretion assay that we had previously established to test putative mutations. 21 We first confirmed that a highly polymorphic variant found across cohorts (COL4A1
Q1334H
) did not significantly alter the extracellular to intracellular ratio when compared to the control cDNA sequence (NM_001845.2). We then tested 2 rare variants that were found only in our control cohort (COL4A1 A144V and COL4A1 M1531V ) and we did not observe a significant effect of these variants on the extracellular to intracellular ratio. In contrast, with 1 exception (COL4A1 G519R ; discussed below), transfection with COL4A1 cDNA containing validated mutations (Table  3) occurring within the triple helix-forming domain  (COL4A1   G498V   ,  COL4A1  G528E ,  COL4A1  G562E ,   COL4A1  G720D , COL4A1  G755R , and COL4A1   G1236R ) or in the NC1 domain (COL4A1
G1580R
) caused a significant reduction in the ratio of extracellular to intracellular COL4A1 when compared to cells transfected with control cDNA (Fig 2) . Similarly, when we tested the functional consequences of the 2 rare variants found only in our patient cohort (COL4A1 P352L and COL4A1 R538G ), we found that both variants were significantly different from controls (see Fig 2, p < 0.01). Thus, these results support the hypothesis that intracellular COL4A1 accumulation, at the expense of its secretion, is a common consequence of COL4A1 mutations and that the 2 putative mutations identified in our cohort have the same effect on COL4A1 biosynthesis as previously validated mutations.
Discussion
The current study represents the first assessment for a broader involvement of COL4A1 mutations in the etiology of ICH. We resequenced all coding and flanking intervening sequences for the entire COL4A1 gene and identified 2 putative mutations in patients that were not present in 145 ethnically-matched control individuals. Both mutations resulted in missense changes in amino acids that are highly conserved across species. Functional analysis demonstrated that both the COL4A1 P352L and the COL4A1 R538G variants impair secretion of COL4A1.
Proline residues in the Y position of the triple helix- 29 and it may be that the COL4A1 P352L mutation impairs this process. In addition, frequent interruptions in the Gly-Xaa-Yaa repeats are thought to confer flexibility to type IV collagen molecules. COL4A1 has 21 repeat interruptions that align with 23 interruptions in COL4A2. The COL4A1 R538G variant occurs within a repeat interruption and shortens the interruption from a 7-amino acid interruption to a 4-amino acid interruption (from GEP GEF YFDLRLK GDK to GEP GEF YFDL GLK GDK), which could lead to abnormal alignment of peptides within the heterotrimer and therefore interfere with proper heterotrimer assembly and secretion. Our data testing the effects of established mutations on collagen biosynthesis suggest that the intracellular retention of mutant COL4A1 proteins at the expense of their secretion appears to be a common effect of many COL4A1 mutations. The extents to which intracellular and/or extracellular insults contribute to pathology remain an open question. Intracellular accumulation of COL4A1 could lead to cytotoxic stress. On the other hand, deficiency of COL4A1 or the presence of mutant COL4A1 in the extracellular matrix could also have detrimental consequences. For example, reduced or mutant COL4A1 in the basement membrane could physically compromise blood vessels 30 or disrupt protein-protein interactions with extracellular molecules, including other basement membrane components, growth factors, 31, 32 or cell-surface receptors. The absence of morphologically engorged endoplasmic reticulum in a renal biopsy from a patient with a COL4A1 G498V mutation led to the hypothesis that mutations clustering near putative integrin binding domains, and which have been associated with HANAC syndrome, might act on integrin signaling. 13 Here, we have tested 3 of these mutations (COL4A1
G498V
, COL4A1 G519R , and COL4A1 G528E ) for the efficiency with which the mutant proteins are secreted. We find that 2 of these mutations, including COL4A1
, have significant decreases in the extracellular to intracellular COL4A1 ratio, while the COL4A1 G519R mutation shows a trend toward a reduced ratio that was not statistically significant (see Fig 2) . This apparent discrepancy may reflect that, in vivo, cells do not have intracellular accumulation like we detected in vitro. It might also be that there is accumulation of COL4A1 in vivo but that the effect is transient or not fully penetrant and its detection requires a much larger sample size for electron microscopy than can be practically accomplished in human biopsies. Therefore, it may be that this subset of COL4A1 mutations do not affect protein folding in vivo; however, the evidence to date is inconclusive. Interestingly, the COL4A1 R538G variant identified in 1 of our patients also occurs within a putative integrin-binding site (GEFYFDLRLKGDK). 33, 34 However, this mutation shortens the length of a repeat interruption and leads to strong intracellular accumulation, so the potential significance of any effect on the putative integrin-binding site is not clear. Therefore, although protein misfolding is associated with most COL4A1 mutations, the precise molecular mechanisms by which mutations lead to cerebrovascular diseases are still unknown and may exhibit allelic and mechanistic heterogeneity. Determining allelic and mechanistic heterogeneity of COL4A1 mutations will be important for developing innovative therapeutics to prevent ICH in patients. To this end, evaluating if genotype-phenotype correlations exist between different mutant alleles in mice maintained on a uniform genetic context and under controlled environmental conditions could be important for understanding the pathogenic mechanisms contributing to COL4A1-related pathologies. Moreover, irrespective of the location of the insult (intracellular, extracellular, or both) it is possible that conditions that promote protein folding will both reduce intracellular accumulation and increase extracellular secretion, thereby having a beneficial effect. Indeed this proved to be the case in C. elegans with mutations in Col4a1 and Col4a2 orthologs, whereby pathology was rescued by growth at reduced temperatures. [35] [36] [37] These data suggest that chemical chaperones or other small molecules that promote protein folding could be efficacious in reducing the risk of ICH in some patients with COL4A1 mutations. ), an established pathogenic mutation (COL4A1 G562E ) or a common variant (COL4A1 Q1334H ). A total of 6 independent clones for each variant were used for this analysis, *p < 0.05, **p < 0.01. Both putative mutations, COL4A1 P352L and COL4A1
R538G
, had significant reductions in the extracellular to intracellular ratio of COL4A1 (p < 0.01) when compared to control (2-tailed Student t test).
